News

ERC puts €680m into research
Enlarge image

FundingSwitzerlandEU

ERC puts €680m into research

24.01.2013 - The European Research Council (ERC) has awarded €680m to 302 top basic researchers in 24 EU countries.

The awards are part of the latest series of the ERC’s Advanced Grants, which give up to €2.5m per researcher to pursue ground-breaking ideas at the frontiers of knowledge. Life Science researchers were very successful in this call, bagging 37% of the total funding cake. However, at only 13%, the ERC grant’s success rate is very low compared to other funding programmes. The European Commission has proposed to expand the ERC's budget significantly in its 2014-2020 innovation programme Horizon 2020. Negotiations with the member states about the long-term EU budget including Horizon2020, however, were cancelled at the end of last year. This is why the ERC has now begun to extend its lobbying activities.

ERC representative Helga Nowotny, thus, for the first time attended the World Economic Forum (WEF) in Davos to embrace industry and policymakers. ”The health and wealth of future societies greatly depend on maintaining the long-term perspectives that science offers,“ said ERC chief Nowotny.."Investment in research, education and innovation is even more important in times of budgetary austerity, in Europe and elsewhere. Leaders from all fields, including business, understand this dynamic, but need to find novel ways of joining forces. We truly believe that science, as well as technology and innovation, will emerge as a common theme of interest to shape the agenda of the future decades”.

The idea to catalyse actions for putting science, technology and innovation on the global agenda has already started and is likely to be prominent in this year's forum. There is growing awareness amongst policy-makers worldwide and public research organisations, of the fact that globalisation of science offers unprecedented opportunities for cooperation. In Davos, one of the sessions will be devoted to how decision-makers, business, civil society and academia can join forces to build a new vision based on frontier research, scientific discoveries and innovation.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/erc-funds-researchers-with-eur680m.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

BusinessSwedenFrance

02.06.2015 After disappointing Phase III results for immunotherapy tasquinimod and the subsequent discontinuation of the prostrate cancer drug, Swedish Active Biotech is now severely downsizing its operations.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

EPOSwitzerland

30.05.2015 Pharma giant Roche has out-licensed its anaemia drug Mircera to fellow Swiss healthcare company Galenica.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • NEOVACS (F)1.25 EUR15.74%
  • SCANCELL HOLDINGS (UK)38.25 GBP14.18%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-53.97%
  • ANTISOMA (UK)1.00 GBP-35.48%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • HYBRIGENICS (F)1.86 EUR44.2%
  • GALAPAGOS (B)51.13 EUR36.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-56.7%
  • CYTOS (CH)0.61 CHF-39.6%
  • ANTISOMA (UK)1.00 GBP-35.5%

TOP

  • CELLECTIS (F)38.35 EUR509.7%
  • WILEX (D)4.30 EUR497.2%
  • ADOCIA (F)69.01 EUR451.6%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-81.8%
  • THROMBOGENICS (B)5.32 EUR-70.0%
  • ACTIVE BIOTECH (S)10.60 SEK-68.6%

No liability assumed, Date: 02.06.2015